U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O3S
Molecular Weight 80.063
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge -2

SHOW SMILES / InChI
Structure of SULFITE ION

SMILES

[O-]S([O-])=O

InChI

InChIKey=LSNNMFCWUKXFEE-UHFFFAOYSA-L
InChI=1S/H2O3S/c1-4(2)3/h(H2,1,2,3)/p-2

HIDE SMILES / InChI

Molecular Formula H2O3S
Molecular Weight 82.079
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sulfites are compounds that contain the sulfite ion. The sulfite ion is the conjugate base of bisulfite. Although its acid is elusive, its salts are widely used. Sulfite is used in the photography industry to protect developing solutions from oxidation, in the pulp and paper industry, in water treatment as an oxygen scavenger agent, as a desulfurizing and dechlorinating agent in the leather industry and as a bleaching agent in textile industry. Sodium sulfite is a component in many pharmaceuticals, which is effective to maintain the potency and stability of drugs. It is added to a number of drug preparations as an antioxidant and antimicrobial agent. Sulfite is used as a food preservative. Topical, oral or parenteral exposure to sulphites has been reported to induce a range of adverse clinical effects in sensitive individuals, ranging from dermatitis, urticaria, flushing, hypotension, abdominal pain and diarrhoea to life-threatening anaphylactic and asthmatic reactions. Exposure to the sulphites arises mainly from the consumption of foods and drinks that contain these additives; however, exposure may also occur through the use of pharmaceutical products, as well as in occupational settings. Sulfite is accepted for use as a food additive in Europe. Sodium sulfite is generally recognized as safe by FDA. It is included in FDA Inactive Ingredients Database (epidural, IM, IV, and SC injections; inhalation solution; ophthalmic solutions; oral syrups and suspensions; otic solutions; topical creams and emulsions). Included in nonparenteral medicines licensed in the UK.

Approval Year

PubMed

PubMed

TitleDatePubMed
Effect of sulfite on red blood cell deformability ex vivo and in normal and sulfite oxidase-deficient rats in vivo.
2005-09
A mechanism of sulfite neurotoxicity: direct inhibition of glutamate dehydrogenase.
2004-10-08
The effect of a denture adhesive on the colonization of Candida species in vivo.
2003-09
Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.
2001-06-21
Sulfite is released by human neutrophils in response to stimulation with lipopolysaccharide.
1998-11
Ahomocysteinemia in molybdenum cofactor deficiency.
1998-09
Nutritional aspects of dissimilatory sulfate reduction in the human large intestine.
1997-11
Comparison of a new, bismuth-iron-sulfite-cycloserine agar for isolation of Clostridium perfringens with the tryptose-sulfite-cycloserine and blood agars.
1997-02
Metabolism of methanesulfonic acid involves a multicomponent monooxygenase enzyme.
1996-02
Media for Aeromonas spp., Plesiomonas shigelloides and Pseudomonas spp. from food and environment.
1995-06
Effect of sulphite on the oxidative metabolism of human neutrophils: studies with lucigenin- and luminol-dependent chemiluminescence.
1995-01-01
Responses of human neutrophils to sulfite.
1994-03
Molybdenum: an essential trace element.
1993-12
Sulfite stimulates NADPH oxidase of human neutrophils to produce active oxygen radicals via protein kinase C and Ca2+/calmodulin pathways.
1993-06
High performance liquid chromatographic determination of bound sulfide and sulfite and thiosulfate at their low levels in human serum by pre-column fluorescence derivatization with monobromobimane.
1992-11
Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatography of stable o-phthalaldehyde-sulphite derivatives.
1991
High-performance liquid chromatographic measurement of exogenous thiosulfate in urine and plasma.
1984-08-01
Evaluation of differential and selective media for isolation of Aeromonas and Plesiomonas spp. from human feces.
1983-01
[Determination of fibrinogen concentration in blood plasma by the sulfite precipitation method].
1979-01-01
Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE.
1977-04
Patents

Sample Use Guides

The acceptable daily intake for sodium sulfite has been set at up to 350 mg/kg body-weight daily.
Route of Administration: Oral
Sulfite was rapidly converted to sulfate by isolated rat hepatocytes at concentrations ranging from 200 umol/L to 2 mmol/L. Incubation of isolated rat hepatocytes with 0.5, 1, or 2 mmol/L sulfite resulted in a time-dependent increase in the amount of free glutathione, but not cysteine, associated with the cells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:58:04 GMT 2025
Edited
by admin
on Mon Mar 31 20:58:04 GMT 2025
Record UNII
15744271E9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFITE ION
Common Name English
SULFITE (SO32-)
Preferred Name English
SULFUROUS ACID, ION(2-)
Common Name English
SULFITE(2-)
Common Name English
SULFITE DIANION
Common Name English
SULFITE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID4049791
Created by admin on Mon Mar 31 20:58:04 GMT 2025 , Edited by admin on Mon Mar 31 20:58:04 GMT 2025
PRIMARY
FDA UNII
15744271E9
Created by admin on Mon Mar 31 20:58:04 GMT 2025 , Edited by admin on Mon Mar 31 20:58:04 GMT 2025
PRIMARY
CHEBI
17359
Created by admin on Mon Mar 31 20:58:04 GMT 2025 , Edited by admin on Mon Mar 31 20:58:04 GMT 2025
PRIMARY
PUBCHEM
1099
Created by admin on Mon Mar 31 20:58:04 GMT 2025 , Edited by admin on Mon Mar 31 20:58:04 GMT 2025
PRIMARY
CHEBI
26823
Created by admin on Mon Mar 31 20:58:04 GMT 2025 , Edited by admin on Mon Mar 31 20:58:04 GMT 2025
PRIMARY
CHEBI
48854
Created by admin on Mon Mar 31 20:58:04 GMT 2025 , Edited by admin on Mon Mar 31 20:58:04 GMT 2025
PRIMARY
CAS
14265-45-3
Created by admin on Mon Mar 31 20:58:04 GMT 2025 , Edited by admin on Mon Mar 31 20:58:04 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY